141W94

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
A phase I, open-label, dose-escalating trial was conducted to evaluate the safety, tolerability, and pharmacokinetics of single… (More)
Is this relevant?
2000
2000
The therapeutic success of an antiretroviral salvage regimen containing protease inhibitors (PI) is limited by PI-resistant viral… (More)
Is this relevant?
2000
2000
Amprenavir (141W94) is extensively metabolized by P450 cytochromes, specifically, CYP3A4. Because hepatic insufficiency reduces… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
1999
1999
We conducted a double-blind, placebo-controlled, parallel, dose-escalation trial to evaluate the pharmacokinetics and safety of… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Purpose. To determine the role of P-glycoprotein (Pgp) on the CNS penetration of the HIV protease inhibitor (PI) amprenavir… (More)
Is this relevant?
1998
1998
The use of combinations of anti-human immunodeficiency virus (anti-HIV) agents targeted to different molecular targets will most… (More)
Is this relevant?
1998
1998
Amprenavir (141W94, VX-478, KVX-478) is metabolized primarily by CYP3A4 (cytochrome P450 3A4) in recombinant systems and human… (More)
Is this relevant?
1997
1997
  • AIDS treatment news
  • 1997
A new trial of the experimental protease inhibitor 141W94 (VX-478) is being conducted with protease inhibitor-naive patients… (More)
Is this relevant?
1996
1996
141W94 (VX-478) is a novel HIV-1 protease inhibitor with an IC50 of 0.08 microM against HIV-1 (strain IIIB) and a mean IC50 of 0… (More)
Is this relevant?
1996
1996
Compound 141W94 (Vertex VX478) (3S)-tetrahydro-3-furyl N-[((S,2R)-3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl- 2… (More)
Is this relevant?